Acquisition (Details Narrative) - USD ($)		1 Months Ended	2 Months Ended	3 Months Ended		12 Months Ended
	Jul. 02, 2020	Aug. 05, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2021
Acquisition payable			$ 74,589	$ 74,589			$ 1,764,876
Common stock issued during period for acquisition value				175,000
Revenues				8,449,754	$ 2,937,442
Net income (loss)				511,711	(809,073)
Amortized of intangible assets				$ 250,383	209,872
VitaMedica [Member]
Cash payment		$ 2,000,000
Shares of Common stock				100,000
Convertible per share			$ 5.00	$ 5.00
Proceeds from repayment of loans to purchase common stock				$ 500,000
Original principal amount			$ 500,000	$ 500,000
Common stock issued during period for acquisition				100,000
Common stock issued during period for acquisition value				$ 482,000
Operating expenses						$ 413,000
Revenues			881,573
Net income (loss)			119,137	35,596	74,696
Amortized of intangible assets			$ 68,834
Proforma Adjustments [Member]
Net income (loss)					(103,250)
Amortization expense				34,417	$ 103,250
Amortization expense, annually				413,000
Amortization expense, monthly				$ 34,417
September 1,2021 [Member] | Infusionz LLC [Member]
Shares of Common stock				306,945
Common stock per share			$ 5.75	$ 5.75
July 1, 2020 [Member] | Infusionz LLC [Member]
Common stock, percentage of outstanding shares				100.00%
FinderFee [Member]
Cash payment				$ 70,000
Common stock per share			4.82	$ 4.82
Finder's fee				$ 103,740
Common stock issued during period for acquisition				7,000
Common stock issued during period for acquisition value				$ 33,740
Trunano Labs, Inc. Common Stock [Member] | July 1, 2020 [Member]
Common stock issued during period for acquisition value				$ 127,500
Common stock, percentage of outstanding shares	10.80%			10.80%
Convertion of shares into common stocks noncontrolling shareholders	1,761,261			1,761,261
Outstanding stock conversion	1,277,778			1,277,778
Customer lists [Member] | Minimum [Member]
Estimated useful lives				five
Customer lists [Member] | Maximum [Member]
Estimated useful lives				ten years
Purchase method of accounting [Member]
Total estimated fair value				$ 3,556,589
Cash payment				$ 2,000,000
Shares of Common stock				100,000
Common stock per share			$ 4.82	$ 4.82
Purchase price sale of shares			100,000	100,000
Proceeds from issuance of common stock				$ 482,000
Convertible per share			$ 5.00	$ 5.00
Proceeds from repayment of loans to purchase common stock				$ 500,000
Original principal amount			$ 500,000	500,000
Acquisition payable			$ 74,589	$ 74,589